Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$18.77 +4.1%	$21.58	$15.47 ▼ $36.37	$758.48M	1.17	259,434 shs	343,781 shs
IMNM Immunome	$10.18 +1.7%	$9.59	$5.15 ▼ $16.73	$885.81M	1.93	1.01 million shs	204,886 shs
TLSA Tiziana Life Sciences	$2.00 -6.1%	$1.74	$0.63 ▼ $2.60	$233.70M	-0.57	611,846 shs	294,228 shs
TRVI Trevi Therapeutics	$7.50 -1.4%	$6.65	$2.36 ▼ $8.11	$911.52M	0.58	1.83 million shs	571,361 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+6.31%	-5.61%	-17.60%	-6.34%	-22.03%
IMNM Immunome	+1.01%	-4.30%	+17.63%	+25.13%	-26.02%
TLSA Tiziana Life Sciences	-4.05%	-8.58%	+43.92%	+53.24%	+56.62%
TRVI Trevi Therapeutics	+3.68%	+4.54%	+8.42%	+22.78%	+181.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
AVBP ArriVent BioPharma	1.9345 of 5 stars	4.6	0.0	1.7	0.8
IMNM Immunome	1.7498 of 5 stars	3.5	0.0	2.5	2.5
TLSA Tiziana Life Sciences	0.6165 of 5 stars	0.0	3.0	2.5	1.7
TRVI Trevi Therapeutics	3.0497 of 5 stars	4.7	1.0	2.6	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.14	108.60% Upside
IMNM Immunome	3.00	Buy	$23.14	127.40% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A
TRVI Trevi Therapeutics	3.30	Buy	$20.38	171.85% Upside

Current Analyst Ratings Breakdown

Latest TLSA, IMNM, AVBP, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $42.00
8/12/2025	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $33.00
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
7/22/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$6.16 per share	N/A
IMNM Immunome	$9.04M	97.99	N/A	N/A	$3.09 per share	3.29
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$4.02	N/A	N/A	N/A	N/A	-55.40%	-51.97%	N/A
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/13/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	N/A

Latest TLSA, IMNM, AVBP, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	-$0.90	-$0.20	-$0.90	N/A	N/A
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	12.74	14.34
IMNM Immunome	N/A	12.13	12.13
TLSA Tiziana Life Sciences	N/A	1.02	1.02
TRVI Trevi Therapeutics	N/A	22.42	22.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
IMNM Immunome	44.58%
TLSA Tiziana Life Sciences	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
IMNM Immunome	7.69%
TLSA Tiziana Life Sciences	39.82%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	40.57 million	27.86 million	N/A
IMNM Immunome	40	87.04 million	80.35 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable
TRVI Trevi Therapeutics	20	121.78 million	99.49 million	Optionable

TLSA, IMNM, AVBP, and TRVI Headlines

Recent News About These Companies

Persistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13 at 7:06 AM | marketbeat.com

Informed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13 at 6:27 AM | marketbeat.com

Trevi Therapeutics: Optimism Amid Earnings Call Insights

August 13 at 4:44 AM | msn.com

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)

August 13 at 4:44 AM | theglobeandmail.com

HC Wainwright Analysts Increase Earnings Estimates for TRVI

August 12 at 4:55 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 11 at 2:33 PM | marketbeat.com

Needham & Company LLC Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

August 11 at 2:09 AM | americanbankingnews.com

Raymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

August 10, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

August 10, 2025 | finance.yahoo.com

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00

August 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | prnewswire.com

41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbH

August 4, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in July

August 2, 2025 | marketbeat.com

Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

August 2, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What Happened

August 1, 2025 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

July 31, 2025 | prnewswire.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 29, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Time to Buy?

July 24, 2025 | marketbeat.com

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

July 11, 2025 | zacks.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, IMNM, AVBP, and TRVI Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$18.76 +0.75 (+4.13%)

As of 03:00 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immunome NASDAQ:IMNM

$10.18 +0.17 (+1.67%)

As of 03:01 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Tiziana Life Sciences NASDAQ:TLSA

$2.00 -0.13 (-6.10%)

As of 03:00 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Trevi Therapeutics NASDAQ:TRVI

$7.50 -0.11 (-1.38%)

As of 03:01 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time